Agnes Muskens-Heemskerk's research while affiliated with Erasmus MC and other places

Publications (5)

Article
High-sensitivity C-reactive protein (hs-CRP) and B-type natriuretic peptide (BNP) are useful biomarkers for cardiovascular risk stratification. Little data are available regarding the prognostic value of hs-CRP and BNP serum levels and future ventricular arrhythmic events triggering implantable cardioverter defibrillator (ICD) therapy. A total of 1...
Article
Objective: Implantable cardioverter-defibrillators (ICDs) prevent arrhythmic death, but do not modify disease progression. The prevalence of persistent cardiovascular risk factors in patients receiving an ICD and their adherence to optimal pharmacological therapy at late follow-up is unknown. The aim of this study was to assess the prevalence of c...
Article
Full-text available
The benefit of implantable defibrillators (ICDs) for primary prevention remains debated. We analysed the implications of prophylactic ICD implantation according to the guidelines in 2 tertiary hospitals, and made a healthcare utilisation inventory. The cohort consisted of all consecutive patients with coronary artery disease (CAD) or dilated cardio...
Article
Full-text available
Implantable cardioverter-defibrillators (ICDs) reduce mortality in both primary and secondary prevention, but are associated with substantial short- and long-term morbidity. A totally subcutaneous ICD (S-ICD) system has been developed. We report the initial clinical experience of the first 31 patients implanted at our hospital. All patients had an...

Citations

... In secondary prevention of SUD, in patients with sustained ventricular tachycardia/fibrillation or survivors of sudden cardiac death drug treatment alone is ineffective and can be used as an adjunct to ICD to decrease episodes of ventricular tachycardia/fibrillation and non-sustained ventricular tachycardia to reduce ICD discharge, to slow the rate of ventricular tachycardia and to increase haemodynamic stability. 96,99 Patients with advanced heart failure and low LVEF in which symptoms progress despite optimal pharmacotherapy and ICD device implantation may benefit in future from devices engineered to restore sympathovagal balance to the heart by electrical neuromodulation. Several options have been investigated in animal models, involving baroreflex activation therapy (BAT) and vagal stimulation. ...
... In addition, a positive association between higher serum hs-CRP level and the occurrence of ventricular arrhythmias was found in a prospective cohort study on implantable cardioverter defibrillator recipients (11). Additionally, higher CRP levels increasing the risk of ventricular arrhythmia has been previously described in the literature (12)(13)(14); however, the mechanisms underlying this association remain unclear. In a population-based sample, Vianello et al (15) found a negative association between CRP level and serum calcium concentration, suggesting that calcium homeostasis imbalance induced by CRP may contribute to arrhythmia. ...
... [8][9][10] This can be explained by longer follow up, underreporting of complications and implantation in more difficult patients who, in contrast to clinical trials, are not excluded from the potential benefit of a device. 10,14 However, in the United States a decreasing number of complications is seen in registry data. 8 One of the most feared complications is infection, and many of the cited complications will increase the risk for infection, especially in patients undergoing generator change and placement of additional leads. ...
... The advantage of S-ICDs concerns the components, which are completely outside of the chest. This substantial difference minimizes the risk of lead fractures or systemic infections, some of the most feared complications of TV-ICDs [3], as well as making any extraction procedure much simpler and less dangerous [4]. Consequently, the outlook for S-ICDs is stronger in two scenarios: when used in younger patients, who are usually affected by genetic heart diseases and are at high risk of sudden cardiac death (SCD) such as hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and genetic arrhythmia syndromes [5][6][7]; and in instances in which the transvenous route is inaccessible. ...
... Of the 37 included studies, 11 trials dealt with patients with newly implanted pacemaker [22][23][24][25][26][27][28][29][30][31][32], 11 trials analyzed patients with new ICDs [33][34][35][36][37][38][39][40][41][42][43] and 15 trials examined patients with new LVADs [44][45][46][47][48][49][50][51][52][53][54][55][56][57][58]. In total, 7 of the 39 trials had control groups not receiving the respective devices while all other trials were cohort studies with longitudinal data acquisition of patients before and after implantation. ...